GlassScriptPhysician profile
Jean E Taggart
NPI 1497465942
$2,962.38
in general payments reported to CMS, 2019-2025
29 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.54 · 2023: $1,722 · 2024: $896 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $639.87 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $425.42 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $293.45 | 2023-2025 | |
| Mannkind Corporation | $207.77 | 2022-2023 | Afrezza |
| Insulet Corporation | $205.27 | 2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $152.04 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $143.41 | 2023-2025 | Yorvipath |
| Amgen INC. | $134.40 | 2024-2025 | Repatha, Repatha |
| Dexcom, INC. | $133.87 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $115.87 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.92 | 2023-2024 | Jardiance |
| Aimmune Therapeutics, INC. | $53.86 | 2024 | |
| Corcept Therapeutics | $44.78 | 2022-2023 | Korlym |
| Amarin Pharma, INC. | $39.73 | 2023 | |
| Sanofi-Aventis U.S. LLC | $32.47 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $32.24 | 2023-2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $32.17 | 2023 | |
| Neurocrine Biosciences, INC. | $27.85 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.17 | 2023-2024 | Strensiq |
| Amneal Pharmaceuticals LLC | $19.02 | 2023 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $18.25 | 2024 | Crysvita |
| Pfizer INC. | $17.77 | 2023 | |
| Kyowa Kirin, INC. | $17.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.68 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.76 | 2024 | Evkeeza |
| Verity Pharmaceuticals INC. | $15.27 | 2024 | Tlando |
| Acella Pharmaceuticals, LLC | $15.00 | 2025 | NP Thyroid 60 |
| Medtronic, INC. | $14.59 | 2022 | |
| Tolmar, INC. | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Taggart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.